Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 7/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 6/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863944 | 0.86 | FLT1 (0.52) | F10KDRFLT1MTORKIT | |
| SCHEMBL4041551 | 0.86 | F10 (0.47) | F10KDRFLT1MTORWNT3A | |
| SCHEMBL4041555 | 0.84 | F10 (0.45) | F10KDRFLT1MTORWNT3A | |
| SCHEMBL2229333 | 0.84 | KDR (0.67) | F10KDRFLT1WNT3AKIT | |
| SCHEMBL4035217 | 0.81 | HDAC3 (0.47) | F10KDRFLT1MTORKIT | |
| SCHEMBL13979163 | 0.81 | FLT1 (0.50) | F10KDRFLT1MTORWNT3A | |
| SCHEMBL6543856 | 0.81 | FLT1 (0.51) | F10KDRFLT1KITABL1 | |
| SCHEMBL5855436 | 0.80 | F10 (0.47) | F10KDRFLT1MTORWNT3A | |
| SCHEMBL3869133 | 0.80 | KIT (0.59) | F10KDRFLT1KITABL1 | |
| SCHEMBL4036764 | 0.79 | FLT1 (0.51) | KDRFLT1KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7148357-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | FLT4, KDR, FLT1 | F10 1841/4885KDR 2/4885FLT1 3/4885 |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | F10 2575/4885KDR 2/4885FLT1 3/4885 |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | F10 1968/4885KDR 2/4885FLT1 3/4885 |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | F10 1980/4885KDR 2/4885FLT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.